Difficulty: Medium
Average Score: 87%
Testbank
The nurse is preparing to administer orlistat to a client with obesity. Which safety warning(s) should the nurse consider when administering this medication to the client? Select all that apply.
Correct answer
A,B,C
Rationale
Administer orlistat with meals and stagger its administration with other drugs to enhance absorption and reduce potential interactions.
Correct Option Explanation: Orlistat is designed to inhibit fat absorption when taken with meals, thus ensuring its efficacy. Staggering administration with other medications is essential to minimize interactions that could compromise the therapeutic effects of either orlistat or the concomitant drugs.
B: Provide a vitamin supplement with the medication. While vitamin supplementation may be beneficial due to potential fat-soluble vitamin malabsorption, it is not a primary safety warning associated with orlistat administration.
C: Monitor liver function. Although liver function should be monitored in certain circumstances, it is not a specific safety warning directly tied to the administration of orlistat in all clients.
D: Avoid caffeine. There is no direct contraindication or safety warning regarding caffeine consumption related to orlistat use, making this option irrelevant in the context of the medication's administration.
E: Avoid use among clients with heart disease, hypertension, and hyperthyroidism. Orlistat does not carry specific contraindications for these conditions, so this option does not align with the critical safety warnings for administering the medication.
Correct Option Explanation: Orlistat is designed to inhibit fat absorption when taken with meals, thus ensuring its efficacy. Staggering administration with other medications is essential to minimize interactions that could compromise the therapeutic effects of either orlistat or the concomitant drugs.
B: Provide a vitamin supplement with the medication. While vitamin supplementation may be beneficial due to potential fat-soluble vitamin malabsorption, it is not a primary safety warning associated with orlistat administration.
C: Monitor liver function. Although liver function should be monitored in certain circumstances, it is not a specific safety warning directly tied to the administration of orlistat in all clients.
D: Avoid caffeine. There is no direct contraindication or safety warning regarding caffeine consumption related to orlistat use, making this option irrelevant in the context of the medication's administration.
E: Avoid use among clients with heart disease, hypertension, and hyperthyroidism. Orlistat does not carry specific contraindications for these conditions, so this option does not align with the critical safety warnings for administering the medication.